BioSpace News Archive

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 401,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd).

Pliant Therapeutics, Inc. today announced a late-breaking presentation of results from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) at The Liver Meeting ® 2023 of the American Association.

Lirum Therapeutics, Inc. announced today that Peter McDonald, the CEO of Lirum, will present at the 2023 ThinkEquity Conference on Thursday, October 19, 2023, at 2:00 PM ET.

Waters Corporation announces the launch of OligoWorks™ SPE Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides.

RegCell announced the appointment of Michael V. McCullar, Ph.D., MBA as its new President, Chief Executive Officer, and Representative Director.

Equillium, Inc. today announced that abstracts were accepted for poster presentations at the annual meetings of the American Society of Nephrology (ASN) and the American College of Rheumatology (ACR).

Avinger, Inc. today announced that it will release its financial results for the third quarter 2023 after the close of trading on Thursday, October 26, 2023.

Persephone Biosciences Inc. today announced the launch of its Food as Medicine clinical study, AMBROSIA (NCT06091813).

Vaxcyte, Inc. (Nasdaq: PCVX) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s adult Investigational New Drug (IND) application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).